Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,621 INR | +1.02% | +4.60% | +28.67% |
Mar. 19 | Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia | MT |
Mar. 19 | Sun Pharmaceutical's Acne Drug Gets Approval in Australia | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 41.39 and 34.2 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.67% | 46.19B | B- | ||
+18.57% | 22.88B | B+ | ||
+20.11% | 14.18B | B+ | ||
+0.55% | 12.63B | - | ||
+46.16% | 12.07B | B | ||
-1.55% | 7.85B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+7.80% | 5.14B | B+ | ||
+6.29% | 4.64B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Sun Pharmaceutical Industries Ltd. - NSE India S.E.
- Ratings Sun Pharmaceutical Industries Ltd.